High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T. Bate-Eya, M. Emmy M. Dolman|Oncotarget|2016Cited by 61
Sustained cancer‐relevant alternative <scp>RNA</scp> splicing events driven by <scp>PRMT5</scp> in high‐risk neuroblastomaLaurel T. Bate-Eya, Nicholas B. La Thangue|Molecular Oncology|2024Cited by 2